Boardroom Alpha
Boardroom Alpha
OHI · Current Report (Form 8-K) · Filed June 5, 2026

Omega Healthcare Investors Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 5, 2026
Period
Jun 5, 2026
Ticker
OHI
Accession
0001104659-26-070979
Boardroom Alpha · Filing insights

Omega's 2026 annual meeting results: directors elected; EY ratified; say-on-pay approved; updated 5% ownership disclosures.

About Omega Healthcare Investors Inc
Market cap
$13.9B
1Y TSR
+22.6%
3Y TSR
+23.3%
Board grade
B
Sector
Real Estate
CEO
Matthew Paul Gourmand
Last annual meeting: Jun 5, 2026 · View full Omega Healthcare Investors Inc profile →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 5, 2026

 

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in its charter)

 

Maryland 1-11316 38-3041398
(State or other jurisdiction of
incorporation)
(Commission File Number)

(IRS Employer

Identification No.)

 

303 International Circle,

Suite 200

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

 

(410) 427-1700

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act.

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

     
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $.10 par value OHI New York Stock Exchange

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

On June 5, 2026, Omega Healthcare Investors, Inc. (“Omega” or the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the holders of 255,926,290 shares of Omega’s common stock were present in person or represented by proxy, representing approximately 85.93% of the total outstanding common stock as of the record date for the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:

 

Proposal 1: Election of Directors

 

  FOR AGAINST ABSTENTIONS BROKER NON-VOTES
Kapila K. Anand 207,267,529 6,458,915 372,859 41,826,987
Craig R. Callen 206,030,608 7,709,158 359,537 41,826,987
Dr. Lisa C. Egbuonu-Davis 209,507,298 3,824,288 767,717 41,826,987
Barbara B. Hill 206,904,705 6,837,458 357,140 41,826,987
Kevin J. Jacobs 212,039,448 1,703,885 355,970 41,826,987
C. Taylor Pickett 211,101,005 2,613,356 384,942 41,826,987
Stephen D. Plavin 198,442,058 15,286,082 371,163 41,826,987
Burke W. Whitman 208,122,149 5,606,187 370,967 41,826,987

 

Proposal 2: Proposal to Ratify the Selection of Ernst & Young LLP as Omega’s Independent Registered Public Accounting Firm for the Year Ending December 31, 2026

 

For Against Abstentions Broker Non-Votes
240,521,117 14,949,017 456,156 Not applicable

  

Proposal 3: Advisory Vote on Executive Compensation

 

For Against Abstentions Broker Non-Votes
202,883,780 10,248,851 966,672 41,826,987

 

Each of the director nominees was elected, the selection of Ernst & Young LLP was ratified and Omega’s executive compensation was approved on an advisory basis.

 

Item 8.01Other Events.

 

The Company is providing updated information regarding the beneficial ownership of its common stock by directors, executive officers, and holders of more than 5% of the Company’s outstanding shares. On March 27, 2026, The Vanguard Group filed an amendment to its Schedule 13G reporting that it no longer had, or was deemed to have, beneficial ownership of the Company’s shares based on an internal corporate realignment. After the Company filed its proxy statement for the Annual Meeting, two affiliated entities of The Vanguard Group reported beneficial ownership, on a disaggregated basis, of more than 5% of the Company’s outstanding common stock. The Company has determined to update the beneficial ownership information for all persons known to the Company to be the beneficial owner of more than 5% of the Company’s outstanding common stock to reflect the most current Schedule 13G filings available as of the date of this report.

 

Based on this information and Schedule 13G filings with respect to the Company’s common stock, the beneficial ownership of the Company’s common stock as of April 8, 2026, for all persons known to the Company to be the beneficial owner of more than 5% of the Company’s outstanding common stock, is set forth in the following table:

 

 

 

 

 

Common Stock 

Beneficially Owned(1) 

 
  Number of Shares Percentage of Class

Percent of Class

Including Common

Stock Equivalents(1)

5% Beneficial Owners:      
Vanguard Portfolio Management 27,160,324(2) 9.1% 8.6%
Vanguard Capital Management 15,689,615(3) 5.3% 5.0%
BlackRock, Inc. 31,867,200(4) 10.7% 10.1%

 

(1)As of April 8, 2026, there were 297,799,835 shares of common stock outstanding and no preferred stock outstanding, as well as 16,284,278 common stock equivalents (including OP Units) outstanding.

 

(2)Based on a Schedule 13G filed with the SEC on April 29, 2026, Vanguard Portfolio Management, including on behalf of certain affiliates, reported sole voting power with respect to 37,207 shares and sole dispositive power with respect to 27,160,324 shares. Vanguard Portfolio Management is located at 100 Vanguard Blvd, Malvern, PA, 19355.

 

(3)Based on a Schedule 13G filed with the SEC on April 30, 2026, Vanguard Capital Management, including on behalf of certain affiliates, reported sole voting power with respect to 2,455,494 shares and sole dispositive power with respect to 15,689,615 shares. Vanguard Capital Management is located at 100 Vanguard Blvd, Malvern, PA, 19355.

 

(4)Based on a Schedule 13G/A filed with the SEC on April 30, 2025, BlackRock, Inc., including on behalf of certain subsidiaries, reported sole voting power with respect to 30,899,385 shares and sole dispositive power with respect to 31,867,200 shares. BlackRock, Inc. is located at 50 Hudson Yards, New York, NY 10001.

 

 

[The balance of this page intentionally left blank]

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OMEGA HEALTHCARE INVESTORS, INC.
     
Dated: June 5, 2026 By: /s/ Gail D. Makode
    Gail D. Makode
    Chief Legal Officer, General Counsel

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Omega Healthcare Investors Inc (OHI)

Reference

Frequently asked questions

When did Omega Healthcare Investors Inc file this 8-K?
Omega Healthcare Investors Inc (OHI) filed this Current Report (Form 8-K) with the SEC on June 5, 2026. The accession number assigned by EDGAR is 0001104659-26-070979.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Omega's 2026 annual meeting results: directors elected; EY ratified; say-on-pay approved; updated 5% ownership disclosures. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Omega Healthcare Investors Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Omega Healthcare Investors Inc has filed under CIK 888491, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer